XPHvsETF 2ETF Comparison
VS
Choose a second ETF to run a side-by-side ETF comparison with XPH, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
Find out how industry players manage ETF portfolios. Discover our library of Model portfolios
XPH performance and flow charts
Performance
Cumulative Flows
Historic performance and flows
Data as of 10/27/2026
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | XPH ETF 2 | -4.31%– | -6.56%– | +14.29%– | +30.94%– | +86.70%– | +44.35%– |
| Flows | XPH ETF 2 | -$80M– | +$11M– | +$186M– | +$206M– | +$160M– | +$157M– |
Volatility and drawdown
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | XPH ETF 2 | +22.82%– | +23.36%– | +20.82%– | +21.10%– |
| Max drawdown | XPH ETF 2 | -16.58%– | -16.58%– | -23.45%– | -30.87%– |
| Max drawdown duration | XPH ETF 2 | 69d– | 69d– | 322d– | 1452d– |
Trading data
XPH | ETF 2 | |
Last sale 10/28/2026 at 1:30 PM | $64.55 | – |
| Previous close 10/27/2026 | $63.96 | – |
| Consolidated volume 10/27/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Replication quality
Data as of September 30, 2026
1-year trailing difference
Create an account to view replication metrics
Join for free
XPH | ETF 2 | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
Advertisement
Main metrics
Last update 10/28/2026 at 1:30 PM
Live
Closed
XPH | ETF 2 | |
|---|---|---|
| Last price | $64.55 | – |
| 1D performance | +0.92% | – |
| AuM | $447.54 M | – |
| E/R | 0.35% | – |
Characteristics
XPH | ETF 2 | |
|---|---|---|
| Management strategy | Passive | – |
| Provider | State Street Investment Management | – |
| Benchmark | S&P Pharmaceuticals Select Industry Index | – |
| N° of holdings | 62 | – |
| Asset class | Equities | – |
| Trailing 12m distribution yield | Join | Join |
| Inception date | June 19, 2006 | – |
| ESG | No | – |
Advertisement
Exposure
Countries
XPH
USA
89.77%
Other
10.23%
ETF 2
Sectors
XPH
Healthcare
93.27%
Other
6.73%
ETF 2
Diversification
XPH
Total weight of top 15 holdings out of 15
34.13%
ETF 2
–
Top 15 holdings
Data as of August 31, 2026
XPH
Amylyx Pharmaceuticals, Inc.
3.65%
Crinetics Pharmaceuticals, Inc.
3.60%
MBX Biosciences, Inc.
2.89%
Omeros Corp.
2.68%
Enliven Therapeutics, Inc.
2.28%
Nuvation Bio, Inc.
2.12%
Corcept Therapeutics, Inc.
2.11%
Eton Pharmaceuticals, Inc.
2.08%
Perrigo Co. Plc
1.91%
Edgewise Therapeutics, Inc.
1.85%
Nektar Therapeutics
1.83%
Merck & Co., Inc.
1.81%
Trevi Therapeutics, Inc.
1.80%
Tarsus Pharmaceuticals, Inc.
1.76%
Bristol Myers Squibb Co.
1.75%
ETF 2
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
Advertisement
Latest news about XPH
Donald Trump’s Executive Orders: ETF Bulls and Bears
January 24, 2025
XPH
Analyzing the Potential ETF Winners & Losers from The Weight-Loss Drug Craze
November 20, 2023
XPH
Advertisement
Advertisement
